Article

Biosimilar Savings Highlight Specialty Pharmacy Week in Review

Author(s):

Davy James, Managing Editor

Most read articles of the week on Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/biosimilar-savings-highlight-specialty-pharmacy-we" target="_blank">View the story "Biosimilar Savings Highlight Specialty Pharmacy Week in Review" on Storify</a>]

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © utah51 - stock.adobe.com
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Patient taking prescription medicine -- Image credit: Rawpixel.com | stock.adobe.com
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Naloxone concept represented by wooden letter tiles.
Related Content
Lymphoma, Rituximab, Biosimilar, Hematology | Image Credit: ©freshidea | stock.adobe.com
November 21st 2024

Clinical Safety Data Show Switching Between Rituximab Biosimilars Does Not Increase Adverse Events

Ashley Gallagher, Associate Editor
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Associate Editor
Sjogren Disease, FDA, Nipocalimab, Lupus, Rheumatoid Arthritis | Image Credit: © fizkes | stock.adobe.com
November 19th 2024

FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease

Ashley Gallagher, Associate Editor
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations
January 25th 2024

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Biosimilar, Ocrelizumab, Multiple Sclerosis | Image Credit: ralwel - stock.adobe.com
November 12th 2024

Proposed Biosimilar to Ocrelizumab Shows Comparability With Reference Product

Ashley Gallagher, Associate Editor
Diabetes, Cagrilintinide, Semagliutide | Image Credit: millaf - stock.adobe.com
November 11th 2024

An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 Trials

Vidhi Patel, PharmD Candidate